Misonix, Inc. (MSON) Shares Bought by Bridgeway Capital Management Inc.
Bridgeway Capital Management Inc. raised its stake in shares of Misonix, Inc. (NASDAQ:MSON) by 24.3% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 68,100 shares of the medical equipment provider’s stock after purchasing an additional 13,300 shares during the quarter. Bridgeway Capital Management Inc. owned approximately 0.72% of Misonix worth $1,260,000 at the end of the most recent reporting period.
A number of other institutional investors also recently modified their holdings of the business. Wells Fargo & Company MN increased its position in Misonix by 1,487.5% during the 3rd quarter. Wells Fargo & Company MN now owns 6,350 shares of the medical equipment provider’s stock valued at $117,000 after purchasing an additional 5,950 shares during the period. Acadian Asset Management LLC increased its position in Misonix by 388.8% during the 3rd quarter. Acadian Asset Management LLC now owns 8,212 shares of the medical equipment provider’s stock valued at $152,000 after purchasing an additional 6,532 shares during the period. BlackRock Inc. increased its position in Misonix by 39.0% during the 2nd quarter. BlackRock Inc. now owns 25,660 shares of the medical equipment provider’s stock valued at $318,000 after purchasing an additional 7,203 shares during the period. Renaissance Technologies LLC increased its position in Misonix by 13.4% during the 2nd quarter. Renaissance Technologies LLC now owns 209,300 shares of the medical equipment provider’s stock valued at $2,595,000 after purchasing an additional 24,754 shares during the period. Finally, ClariVest Asset Management LLC purchased a new position in Misonix during the 3rd quarter valued at $649,000. 15.93% of the stock is currently owned by institutional investors and hedge funds.
A number of research firms have recently weighed in on MSON. Canaccord Genuity began coverage on shares of Misonix in a research report on Friday, August 24th. They issued a “buy” rating and a $24.00 target price on the stock. Craig Hallum began coverage on shares of Misonix in a research report on Tuesday, September 11th. They issued a “buy” rating and a $28.00 target price on the stock. Finally, TheStreet downgraded shares of Misonix from a “c” rating to a “d+” rating in a research report on Friday, September 7th.
NASDAQ:MSON opened at $16.13 on Thursday. Misonix, Inc. has a 1-year low of $8.25 and a 1-year high of $21.43.
Misonix (NASDAQ:MSON) last released its earnings results on Thursday, November 8th. The medical equipment provider reported ($0.29) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.20) by ($0.09). The business had revenue of $9.36 million during the quarter. Misonix had a negative return on equity of 14.05% and a negative net margin of 23.24%.
WARNING: “Misonix, Inc. (MSON) Shares Bought by Bridgeway Capital Management Inc.” was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://www.watchlistnews.com/misonix-inc-mson-shares-bought-by-bridgeway-capital-management-inc/2664064.html.
Misonix Company Profile
Misonix, Inc, together with its subsidiaries, designs, develops, manufactures, and markets therapeutic ultrasonic medical devices in the United States, the Americas, Europe, Middle East, Asia Pacific, Africa, and internationally. The company offers BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells.
Receive News & Ratings for Misonix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Misonix and related companies with MarketBeat.com's FREE daily email newsletter.